Tianeptine - A so-called supplement with dangerous consequences. Our #expert weighs in on 'gas station heroin' warnings

Jan 29, 2024

5 min

C. Michael  White, Pharm.D., FCP, FCCP

Since 2022, the U.S. Food and Drug Administration has been actively urging consumers to avoid purchasing or consuming tianeptine -- a synthetic drug commonly called "gas station heroin" that can mimic the actions of opioids like fentanyl.



Now, the FDA is upping the urgency of it's warnings as vendors continue to market the drug as a so-called "dietary supplement." UConn's C. Michael White, a Distinguished Professor of Pharmacy Practice, spoke with The Conversation about the problem with tianeptine in a must-read Q-and-A:


What is tianeptine and why is it risky?

Tianeptine stimulates the same receptors as well-known opioids such as fentanyl, heroin and morphine. When these drugs make their way from the blood to the brain, they bind to the “mu” type opioid receptor that triggers the sought-after pain relief and euphoria of those drugs as well as the dangerous effects like slowed or stopped breathing.

High doses of tianeptine can bring euphoric effects similar to heroin and can also bring about the dissociative effect – the perception of your mind being disconnected from your surroundings and body – that is reminiscent of ketamine, an anesthetic that has a role in treating post-traumatic stress disorder and depression but has also commonly been abused as a street drug.

Products containing tianeptine are often called “legal high drugs” – sometimes dubbed “gas station drugs” – a term used for all non-FDA-approved synthetic drugs that are sold casually in gas stations, online and elsewhere.



What are the major adverse effects that people can experience?

Data from clinical trials, case reports and poison control centers shows that tianeptine commonly induces agitation. This is typically accompanied by a fast heart rate and high blood pressure, confusion, nightmares, drowsiness, dry mouth and nausea, among other conditions. The most serious adverse events are slowed or stopped breathing, coma, heart arrhythmia and death. When long-term users try to stop tianeptine use, they often experience withdrawal symptoms reminiscent of opioid withdrawal.

Consumers need to be aware that products containing tianeptine may not adhere to good manufacturing practices. This means they could contain lead or have other heavy metal contamination or be contaminated by microorganisms such as salmonella or mold. They could also contain other drug ingredients that are not disclosed. Knowingly or unknowingly combining active ingredients can increase the risk of adverse events.

Additionally, the amount of the active ingredient contained in the product can vary widely, even with the same manufacturer. So past use does not guarantee that using the same amount will provide the same effect.

How are these drugs sold in the US if they are not FDA-approved?

If a drug product is not FDA-approved for prescription or over-the-counter-use, it is the Drug Enforcement Agency that is responsible for controlling market access.

Before the DEA can ban an active ingredient in a drug product, it must be designated Schedule I, meaning the drug has no legitimate medical purpose and has high abuse potential. Manufacturers do not have to alert the DEA before selling their products to U.S. citizens. This means the DEA must detect an issue, identify the products causing the issue, identify the active ingredients in the product in question and do a full scientific review before designating it as Schedule I.

Tianeptine came to market masquerading as a dietary supplement in gas stations and smoke shops, even though it is a synthetic compound. Tianeptine is also sold online allegedly for research purposes and not for human consumption. Tianeptine is undergoing clinical trials for the treatment of pain and depression, but sellers do nothing to make this type of labeling clear to consumers or to restrict purchases to researchers.



What can people do to protect themselves and their families?

Non-FDA-approved products containing synthetic drugs are very risky to use and should be avoided. FDA-approved drugs are available by a prescription from a health professional or over the counter with active ingredients on an approved list.

If someone in a gas station, smoke shop or over the internet touts the benefits of a non-FDA-approved drug product – for pain or anxiety relief, to increase energy or for a buzz – be aware. It could be dangerous the first time you use it, but using it successfully once also doesn’t mean the experience will be the same the next time, and continued use can cause addiction.

If a product is being sold “not for human consumption” or “for research purposes only,” you are at a high risk if you take it. Before you take any dietary supplement, make sure you check the active ingredient to be sure that it is, in fact, a natural product and not a synthetic chemical. If someone you know has bags with unmarked powder, a product labeled for research use or not for human consumption, or tablets or capsules not in standard drug bottles, that is a sign of a potentially dangerous situation.

Standard drug tests sold over the counter are not designed to pick up tianeptine. One of the main reasons that people use these alternative substances of abuse over regular opioids, cannabis or amphetamines is that they are much harder to detect through work- or at-home drug screens by parents, schools, employers, probation officers and so on.

If the DEA is not responding to emerging threats quickly enough, individual states can also act to ban sales of dangerous active ingredients in products. As of January 2024, at least 12 states have banned the sale of tianeptine, according to the FDA, although people in those states can still illegally procure it from the internet. So contacting your state legislators could be a place to start exercising your power to help prevent the harms from these products.



This is an important piece, and if you are looking to know about tianeptine and the threat it poses to consumers in America, then let us help.


Dr. C. Michael White is an expert in the areas of comparative effectiveness and preventing adverse events from drugs, devices, dietary supplements, and illicit substances. Dr. White is available to speak with media -- click on his icon now to arrange an interview today.


Connect with:
C. Michael  White, Pharm.D., FCP, FCCP

C. Michael White, Pharm.D., FCP, FCCP

Head and Distinguished Professor, Department of Pharmacy Practice

Dr. White’s research interests are in drug, dietary supplement, and illicit drug safety, quality, and cost

DietCBDDrug CostsDietary SupplementsCardiovascular Drugs
Powered by

You might also like...

Check out some other posts from University of Connecticut

Reconstruction Reconsidered: Manisha Sinha Brings Historical Context to New Obama Podcast Series featured image

2 min

Reconstruction Reconsidered: Manisha Sinha Brings Historical Context to New Obama Podcast Series

As the United States marks its 250th anniversary, a major new podcast series is drawing renewed attention to the Reconstruction era and its lasting impact on American democracy. Reconstruction: The Unfinished Promise, hosted by Malcolm Gladwell and featuring former President Barack Obama, examines the turbulent decades following the Civil War and the ongoing struggle to define citizenship, equality, and political participation in the United States. Among the historians featured in the series is Manisha Sinha, a leading scholar of the Civil War, abolition, and Reconstruction. Her participation brings decades of research and scholarship to a national audience at a time when Americans are revisiting the people, events, and ideas that shaped the nation. Manisha Sinha is the James L. and Shirley A. Draper Chair in American History at UConn and past president of the Society for Historians of the Early American Republic. She is an expert in American political history, the Civil War, and Reconstruction. View her profile Sinha is the author of The Rise and Fall of the Second American Republic: Reconstruction, 1860–1920, a widely acclaimed examination of Reconstruction that challenges conventional timelines and interpretations of the era. Her work argues that Reconstruction was not confined to the years immediately following the Civil War, but instead represented a broader struggle over democracy, citizenship, civil rights, and political inclusion that continued well into the twentieth century. In interviews discussing her research, Sinha has emphasized the transformative nature of Reconstruction and its importance in understanding the development of modern America. Her scholarship explores how debates over voting rights, constitutional protections, racial equality, and citizenship during Reconstruction continue to influence public life today. As interest in Reconstruction grows through America 250 programming and broader public discussions about democracy and civil rights, Sinha's expertise offers valuable historical context for understanding the era's enduring significance. Connect with an Expert Manisha Sinha is available to discuss: The history and legacy of Reconstruction Why Reconstruction remains relevant today The concept of America's "Second Republic" The evolution of citizenship and voting rights in the United States The relationship between Reconstruction, civil rights, and democratic reform Historical perspectives connected to America 250 commemorations How historians are rethinking the traditional timeline of Reconstruction For journalists and audiences seeking deeper insight into one of the most important periods in American history, Sinha offers expert analysis on the debates, achievements, and unresolved questions that continue to shape the nation more than 150 years later.

Tick Population Surge Raises New Lyme Disease Concerns featured image

2 min

Tick Population Surge Raises New Lyme Disease Concerns

A surge in tick activity across Connecticut is renewing concerns about Lyme disease, prompting experts to examine the environmental factors driving tick populations, the challenges of prevention, and the future role of vaccines. Recently reported by CT Community News and CTNewsJunkie, researchers are seeing unusually high numbers of ticks infected with the bacteria that causes Lyme disease, with infection rates reaching levels typically not observed until peak season. Experts point to a combination of environmental conditions, including a snowy winter that insulated overwintering ticks, milder seasonal temperatures, and continued residential expansion into wooded areas where ticks thrive. According to Dr. David Banach, an infectious disease specialist and epidemiologist at UConn Health, the increase in Lyme disease cases is influenced by multiple factors. While improved reporting may account for some of the rise, environmental conditions continue to play a significant role in the number of infections seen by clinicians each year. “Lyme disease is chronically underreported.” Dr. David Banach Dr. David Banach is an infectious diseases physician who leads UConn Health's Infection Prevention Program and serves as hospital epidemiologist. View his profile The article also explores ongoing efforts to develop new Lyme disease vaccines. Dr. Paulo Verardi, head of UConn's Department of Virology and Vaccinology, notes that vaccines could become an important tool in reducing disease risk, but cautions that vaccination alone will not solve the broader challenge posed by expanding tick populations and changing environmental conditions. Effective control, he argues, will require a combination of public education, land management, and efforts to reduce tick abundance. “To really control tickborne diseases, there needs to be more land management, public education and a drop in the overall tick population.” Dr. Paulo Verardi Dr. Paulo Verardi is a virologist who specializes in vaccine research and development. He is a Department Head and Associate Professor at UConn and a member of the Center of Excellence for Vaccine Research. View his profile As Lyme disease continues to spread across North America, understanding the intersection of climate, ecology, public health, and vaccine development is becoming increasingly important. Researchers are working to better understand why tick populations are expanding, how disease risk is changing, and what strategies can best protect people who live, work, and spend time outdoors. Covering Lyme or other tickborne diseases? We can help. To learn more about Lyme disease, tick-borne illnesses, vaccine development, infectious disease trends, and public health preparedness, connect with experts such as Dr. David Banach and Dr. Paulo Verardi, whose research and expertise help explain the growing challenges posed by tick-borne diseases.

Expert Insight: The ‘100 Deadly Days of Summer’ featured image

3 min

Expert Insight: The ‘100 Deadly Days of Summer’

A recent article in the Hartford Courant examining a sudden increase in fatal crashes across Connecticut has transportation safety experts sounding the alarm as the busy summer travel season begins. The story featured Eric Jackson, executive director of the Connecticut Transportation Institute and director of the Connecticut Transportation Safety Research Center, who noted that 16 roadway fatalities were recorded in just nine days — a significant increase that quickly narrowed what had been a year-over-year decline in traffic deaths. Jackson points to a combination of warmer weather, longer days, increased travel, and more vulnerable road users on the road as factors that contribute to what safety professionals often call the "100 Deadly Days of Summer" between Memorial Day and Labor Day. He also warns that motorcycle fatalities may continue to rise as more riders return to the roads, particularly amid higher fuel prices. For journalists covering traffic safety, transportation trends, infrastructure, or public policy, Jackson offers valuable insight into the data, behaviors, and seasonal factors influencing roadway fatalities. The latest data released by the University of Connecticut Crash Repository — which tracks fatal crashes throughout the year — shows that 16 fatalities were reported on Connecticut’s roads between May 10 and May 19, when the numbers were last updated. That many fatal crashes in that short of a time span is a “huge” number and one that “we usually don’t see,” said Dr. Eric Jackson, a research professor at UConn. The overall number of traffic fatalities is still down across the state compared to the same time last year, but the gap has shrunk drastically in the last few weeks, according to Jackson, who serves as the executive director of the Connecticut Transportation Institute and the director of the Connecticut Transportation Safety Research Center. As of May 10, there were 64 traffic deaths reported in 2026 compared to 78 at the same time last year. The most recent data shows that 80 fatal crashes have now been reported so far this year, compared to 83 at the same time in 2025. One potential reason for the drastic uptick in fatalities could be the increased activity that goes along with warmer weather and longer days. “People are out and about more,” Jackson said. During the first several months of the year, cold weather and a number of winter storms could have contributed to keeping many people inside and slowing down those who did go out, Jackson speculated. “Snowstorms, huge weather events usually prevent fatalities because people aren’t driving as fast,” he said.   The trend is especially concerning as higher fuel prices have more people looking to motorcycles as a way to get around in better weather while reducing their fuel consumption. Nine riders have died in Connecticut in the past few weeks, leading some local news outlets to ask: Are high gas prices fueling a rise in deadly motorcycle crashes? Looking to know more?  We can help. Connect with Eric Jackson to discuss seasonal traffic safety trends, motorcycle safety, transportation data analysis, and strategies to reduce roadway fatalities.

View all posts